Journal of Nephrology

, Volume 31, Issue 2, pp 225–230 | Cite as

Influenza and the patient with end-stage renal disease

  • Brendan T. Bowman
  • Mitchell H. Rosner


Influenza is a commonly encountered and serious pathogen. Patients with end-stage renal disease are more susceptible to serious morbidity and mortality associated with influenza infection. Proper management of patients includes: vaccination, monitoring for symptoms and isolation of potentially infected patients as well as appropriate antiviral therapies. In some cases of exposure, chemoprophylaxis is warranted. Vaccination and appropriate therapies are associated with improved outcomes.


Influenza Vaccination End-stage renal disease Chemoprophylaxis 


Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

Human and animal rights

The articles does not contain any studies with any human participants performed by any of the authors.

Informed consent

For this type of study, formal consent is not required.


  1. 1.
    Thompson MG et al (2010) Estimates of deaths associated with seasonal influenza—United States 1976–2007. MMWR 59:1057–1062Google Scholar
  2. 2.
    World Health Organization (2009) Pandemic influenza preparedness and response: a WHO guidance document. WHO, GenevaGoogle Scholar
  3. 3.
    Prevention and Control of Seasonal Influenza with Vaccines (2016) Recommendations of the advisory committee on immunization practices—United States, 2016–2017 influenza season. MMWR 65:1–52CrossRefGoogle Scholar
  4. 4.
    Treanor J (2015) In: Bennett JE (ed) Influenza principles and practice of infectious diseases, 8th edn. Elsevier, PhiladelphiaGoogle Scholar
  5. 5.
    De Clerq E (2007) Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. Trends Pharm Sci 28(6):280–285Google Scholar
  6. 6.
    Cohen YZ, Dolin R (2015) Influenza. In: Kasper D et al (eds) Harrison’s principles of internal medicine, 19th Edn. McGraw-Hill Education, USAGoogle Scholar
  7. 7.
    Subbarao K, Joseph T (2007) Scientific barriers to developing vaccines against avian influneza viruses. Nat Rev Immunol 7:267–278CrossRefPubMedGoogle Scholar
  8. 8.
    York I, Donis RO (2012) The 2009 pandemic influenza virus: where did it come from, where is it now, and where is it going? CRRN Top Mirc Immun 370:241–257Google Scholar
  9. 9.
    Shrestha S et al (2011) Estimating the burden of 2009 pandemic influneza A (H1N1) in the United States (April 2009–April 2010). Clin Infect Dis 52(Supplement):S75–S82CrossRefPubMedGoogle Scholar
  10. 10.
    United States Renal Data System (2016) 2016 USRDS annual data report: epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, BethesdaGoogle Scholar
  11. 11.
    Betjes MG (2013) Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol 9:255–265CrossRefPubMedGoogle Scholar
  12. 12.
    Eleftheriadis T et al (2007) Disturbances in acquired immunity in hemodialysis patients. Semin Dial 20:440–451CrossRefPubMedGoogle Scholar
  13. 13.
    Hauser AB et al (2007) Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int 28(Supplement 3):S183–S187Google Scholar
  14. 14.
    Soni R, Horowitz B, Unruh M (2013) Immunization in end-stage renal disease: opportunity to improved outcomes. Semin Dial 26:416–426CrossRefPubMedGoogle Scholar
  15. 15.
    Jordan MC et al (1973) Immunogenicity of inactivated influenza virus vaccine in chronic renal failure. Ann Intern Med 79:790–794CrossRefPubMedGoogle Scholar
  16. 16.
    Ortbals DW (1978) Influenza immunization in patients with chronic renal disease. JAMA 239:2562–2565CrossRefPubMedGoogle Scholar
  17. 17.
    Antonen JA et al (2000) Adequate seroresponse to influenza vaccination in dialysis patients. Nephron 86:56–61CrossRefPubMedGoogle Scholar
  18. 18.
    Antonen JA et al (2003) Influenza vaccination of dialysis patients: cross-reactivity of induced haemagglutination-inhibiting antibodies to H3N2 subtype antigenic variants is comparable with the response of naturally infected young healthy adults. Nephrol Dial Transplant 18:777–781CrossRefPubMedGoogle Scholar
  19. 19.
    Dinits-Pensy M et al (2005) The use of vaccines in adult patients with renal disease. AJKD 46:997–1011CrossRefPubMedGoogle Scholar
  20. 20.
    Peer Kidney Care Initiative. Peer Report: Dialysis Care and Outcomes in the United States, 2016. Accessed 9 Feb 2017
  21. 21.
    Labriola L et al (2011) Immunocgenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in heamodialysed patients. NDT 26:1424–1428PubMedGoogle Scholar
  22. 22.
    Gilbertson DT et al (2003) Influenza vaccine delivery and effectiveness in end-stage renal disease. Kidney Int 63:738–743CrossRefPubMedGoogle Scholar
  23. 23.
    Bond TC, Spaulding AC, Krisher J, McClellan W (2012) Mortality of dialysis patients according to influenza and pneumococcal vaccination status. Am J Kidney Dis 60:959–965CrossRefPubMedGoogle Scholar
  24. 24.
    McGrath LJ et al (2012) Influenza vaccine effectiveness in patients on hemodialysis: an analysis of a natural experiment. Arch Intern Med 172:548–554CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Wang I et al (2016) Seasonal influenza vaccination is associated with reduced morbidity and mortality in peritoneal dialysis patients. NDT 31:269–274PubMedGoogle Scholar
  26. 26.
    Wetmore JB, PEER Kidney Care Initiative Investigators (2016) Trends in infection in dialysis patients. AJKD 67:A13CrossRefGoogle Scholar
  27. 27.
    Remschmidt C, Wichmann O, Harder T (2014) Influenza vaccination in patients with end-stage renal disease: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety. BMC Med 12:1–14CrossRefGoogle Scholar
  28. 28.
    Wiebe C et al (2009) Atypical clinical presentation of H1N1 influenza in a dialysis patient. Lancet 374:1300CrossRefPubMedGoogle Scholar
  29. 29.
    Marcelli D, Marelli C, Richards N (2009) Influenza A(H1N1)v pandemic in the dialysis population: first wave results from an international survey. Nephrol Dial Transplant 24:3566–3572CrossRefPubMedGoogle Scholar
  30. 30.
    Li H, Wang SX (2010) Clinical features of 2009 pandemic influenza A (H1N1) virus infection in chronic hemodialysis patients. Blood Purif 30:172–177CrossRefPubMedGoogle Scholar
  31. 31.
    Cho JH et al (2011) Impact of dialysis modality on the incidence of 2009 pandemic H1N1 influenza in end-stage renal disease patients. Perit Dial Int 31:347–350CrossRefPubMedGoogle Scholar
  32. 32.
    Peer Kidney Care Initiative (2015) Seasonality of hospitalization for pneumonia, influenza, and dialysis access infection. AJKD 65:A67Google Scholar
  33. 33.
    Wakasugi M (2012) High mortality rate of infectious diseases in dialysis patients: a comparison with the general population in Japan. Ther Apher Dial 16:226–231CrossRefPubMedGoogle Scholar
  34. 34.
    ACIP (2011) Antiviral agents for the treatment and chemoprophylaxis of influenza. MMWR 60(1):1–24Google Scholar
  35. 35.
    Thomas B, Hollister AS, Muczynski KA (2010) Peramivir clearance in continuous renal replacement therapy. Hemodial Int 14:339–340CrossRefPubMedGoogle Scholar
  36. 36.
    Robson R et al (2006) The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephol Dial Transplant 21:2556–2562CrossRefGoogle Scholar
  37. 37.
    Patel K et al (2014) Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis. Br J Clin Pharmacol 79:624–635CrossRefPubMedCentralGoogle Scholar
  38. 38.
    Eyler RF, Heung M, Pleva M (2012) Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Pharmacotherapy 32:1061–1069CrossRefPubMedGoogle Scholar
  39. 39.
    Taylor WR, Thinh BN, Anh GT (2008) Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One 3:e3410CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Flannery AH, Thomson B ML (2014) Oseltamivir dosing in critically Ill patients with severe influenza. Ann Pharamcotherapy 48:1011–1018CrossRefGoogle Scholar
  41. 41.
    Rapivab Highlights of Prescribing Information. Accessed 9 Feb 2017
  42. 42.
    Questions and Answers for Health Care Providers: Renal Dosing and Administration Recommendations for Peramivir IV. Accessed 9 Feb 2017
  43. 43.
    Bazan JA et al (2010) Peramivir pharmacokinetics in two critically ill adult patients with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy. Pharmacotherapy 10:1016–1020CrossRefGoogle Scholar
  44. 44.
    Bentley ML et al (2014) Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic. Int J Clin Pharmacol Ther 52:1105–1111CrossRefPubMedGoogle Scholar
  45. 45.
    Scheetz MH et al (2011) Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration. Ann Pharmacother 45(12):E64CrossRefPubMedGoogle Scholar
  46. 46.
    Harper SA et al (2008) Seasonal influenza in adults and children—diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the infectious disease society of America. Clin Infect Dis 48:1003–1032CrossRefGoogle Scholar

Copyright information

© Italian Society of Nephrology 2017

Authors and Affiliations

  1. 1.Division of NephrologyUniversity of Virginia Health SystemCharlottesvilleUSA

Personalised recommendations